Expression of HLA-DR molecules by keratinocytes, and presence of Langerhans cells in the dermal infiltrate of active psoriatic plaques by unknown
EXPRESSION OF HLA-DR MOLECULES BY
KERATINOCYTES, AND PRESENCE OF LANGERHANS
CELLS IN THE DERMAL INFILTRATE OF ACTIVE
PSORIATIC PLAQUES
BY ALICE B. GOTTLIEB,* BEN LIFSHITZ,* SHU MAN FU,t
LISA STAIANO-COICO,4 CHANG YI WANG,' AND D. MARTIN CARTER*
From the *Laboratories of Immunology and Investigative Dermatology, TheRockefeller
University, New York 10021; the *Immunology Program, Oklahoma Medical Research
Foundation, Oklahoma City, Oklahoma 73104; the (Department ofSurgery, New York
Hospital-Cornell Medical Center, New York 10021; and the (Department ofResearch and
Medicine, North Shore University Hospital-Cornell University Medical College,
Manhasset, New York 11030
Psoriasis is a common disease characterized by raised, scaly, erythematous
lesions. The histologic changes include epidermal hyperplasia, inflammatory cell
infiltrates, and increased cell turnover. Previous investigations (1-9) indicate that
immunological injury may be an important mechanism in its pathogenesis.
Immunohistochemical studies reveal that active psoriasis is associated with epi-
dermal influx of activated T cells, and resolution is associated with suppressor T
cells in the epidermis . In both cases, T lymphocytes are in close physical proximity
to epidermal dendritic cells (10).
The importance of HLA-DR molecules in various immunological responses
has been well documented (reviewed in 11). In normal skin, HLA-DR expression
is confined to Langerhans cells with Birbeck granules (12, 13), indeterminate
cells without Birbeck granules (13), and acrosyringeal epithelium (14, 15) . HLA-
DR expression by keratinocytes has been reported (16-19) in several human
dermatoses characterized by mononuclear infiltrates. In the case of psoriasis, a
recent study (20) reported the focal expression of HLA-DR antigens in epidermal
cells. However, the nature of these cells was not well characterized. In view of
the expression of HLA-DR antigens on activated T cells and Langerhans cells
and the presence of those cells in the epidermis of active psoriatic lesions (10),
and the failure of other investigators to identify HLA-DR' keratinocytes (17,
21), we have undertaken a detailed analysis of a large series of patients with
psoriasis . Qualitative studies of tissue sections and quantitative studies of epider-
mal suction blisters revealed HLA-DR expression by keratinocytes in a significant
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proportion of the patients. In general, these patients had more severe disease,
and the abnormality was reversible with successful therapy.
Materials and Methods
Skin Biopsies and Epidermal Suction Blisters.
￿
Biopsies of lesional and normal-appearing
skin from 20 patients with psoriasis vulgaris and one patient with pustular psoriasis of the
von Zumbusch type were taken after informed consent was obtained in compliance with
a protocol approved by The Rockefeller University Hospital Institutional Review Board.
As controls, skin biopsies were also obtained from individuals with other inflammatory
dermatoses, including six cases of advanced scleroderma, three cases of lichen planus, and
one case each of discoid lupus erythematosus, lupus profundus, cutaneous vasculitis,
spongiotic dermatitis, nummular eczema, dermatomyositis, erythema multiforme, and
subcorneal pustular dermatitis.
Epidermal suction blisters from psoriasis patients and normal individuals were generated
with a temperature of 38°C and a negative pressure of 280 pounds per square inch using
an apparatus designed by Dr. Alan Lipton (The Rockefeller University) . Single-cell
suspensions of keratinocytes were obtained by trypsinization of epidermal sheets (22).
Patients received 2-3 wk therapy with topical tar or anthralin and UV-B irradiation .
Two of the patients received 6 mo of treatment with etretinate (I1-cis-retinoic acid,
Hoffman-La Roche, Nutley, NJ). One patient was treated for 2 mo with topical and
systemic corticosteroids, and methotrexate. At the time posttreatment skin biopsies and
suction blisters were obtained, all patients had at least 50% improvement in erythema,
plaque elevation, and scaling.
Immunoreagents. mAb josh 524.4.1 (IgGI) is directed against a nonpolymorphic
determinant of the human HLA-DR molecule, and immunoprecipitates a 29/34 kD
bimolecular complex (23). mAb CM 161 .1 is specific for a determinant on the HLA-DQ
molecule. Sequential immunoprecipitation studies (L. K. L. Jung, unpublished observa-
tion) show that it detects the same molecule as does mAb Leu-10 (Becton Dickinson
Monoclonal Center, Mountain View, CA). Two mAbs directed against IFN-'y were used.
One was purchased from Interferon Sciences, Inc. (New Brunswick, NJ). The other, A7,
was prepared as previously reported (24). mAbs directed against the T3, T4, and T6
molecules and mAb 63D3 were obtained by culturing hybridoma cell lines obtained from
the American Type Culture Collection (Rockville, MD). mAb B1 was purchased from
Coulter Immunology (Hialeah, FL). mAbs OKT8 and FITC-labelled OKT6 were obtained
from Ortho Diagnostic Systems (Raritan, NJ). mAb AT-1 is directed against the IL-2
receptor and is equivalent to anti-Tac (25). FITC and tetramethylrhodamine isothiocya-
nate-labelled Fab'2 fragments ofa goat anti-mouse IgG were purchased from Tago, Inc.,
(Burlingame, CA).
Immunoperoxidase Studies.
￿
Immunoperoxidase studies of formalin-fixed tissue sections
were performed as previously described (26) using the Vectastain ABC immunoperoxidase
staining system (Vector Laboratories, Burlingame, CA).
Immunofluorescence Studies.
￿
Immunofluorescence studies of tissue sections were per-
formed as follows: 6-km-thick frozen tissue sections were fixed in either cold acetone or
phosphate-buffered formalin, and washed in PBS . The sections were incubated with
mouse mAbs for 30-60 min at room temperature, followed by further washes in PBS.
Nonspecific staining was blocked by incubation with a 1 :10 dilution ofnormal goat serum
followed by washes in PBS. The sections were then incubated with FITC-labelled Fab'1
fragments of a goat anti-mouse IgG antibody for 60 min at room temperature, followed
by washes in PBS. Coverslips were mounted with polyvinyl alcohol and read with a Leitz
Ortholux II fluorescence microscope (E. Leitz, Wetzlar, Federal Republic of Germany).
Keratinocytes were tested with mouse mAbs by indirect immunofluorescence as previously
described (27), using either a Leitz Ortholux 2 fluorescence microscope (E. Leitz) or an
Ortho System 50H cell sorter (28) (Ortho Diagnostic Instruments, Westwood, MA).
For double-labelling immunofluorescence experiments, two different types of experi-
ments were performed. In the first, formalin-fixed, washed skin sections were incubatedGOTTLIEB ET AL.
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with mAb josh 524.4.1 for 30 min at room temperature, washed in PBS, and then
incubated with normal goat serum for 30 min at room temperature. Following washing
and incubation for 60 min at room temperature with tetramethyl-rhodamine isothiocya-
nate-labelled Fab' 2 fragments of a goat anti-mouse IgG antibody, skin sections were
washed and then incubated with a 1 :8 dilution of FITC-labelled OKT6 for 30 min at
room temperature. After washing for 90 min in PBS, coverslips were mounted, and slides
were examined. It was possible that the rhodamine-labelled goat anti-mouse IgG antibody
could have reacted with the fluorescein-labelled mAb OKT6. This was assessed by
incubating normal or psoriatic skin sections with the basal layer-reactive mAb EL-2 (22),
followed by incubation with the rhodamine-labelled goat anti-mouse IgG antibody and
then fluorescein-conjugated mAb OKT6. Fluorescein fluorescence was observed on only
epidermal dendritic cells, while rhodamine fluorescence was confined to the basal epider-
mal layer. These findings indicate that the rhodamine-conjugated goat anti-mouse IgG
antibody did not bind significantly to the fluorescein-labelled mAb OKT6. In the second
set of experiments, formalin-fixed, washed skin sections were incubated for 30 min at
room temperature with a 1 :10 dilution of normal goat serum. After washing, they were
incubated with a 1 :4 dilution of tetramethyl rhodamine isothiocyanate-conjugated Fab' 2
fragments of an anti-HLA-DR antiserum (29) for 30 min at room temperature. After
washing, the sections were incubated with a 1 :8 dilution of FITC-labelled OKT6 for 30
min at room temperature. After washing in PBS for 90 min, coverslips were mounted
and slides were examined.
Results
Lesional Psoriatic Skin Contains HLA-DR' Keratinocytes.
￿
Skin sections from 21
patients with active psoriasis were stained with mAb josh 524.4.1, which is
directed against a nonpolymorphic determinant of the HLA-DR molecule. Skin
sections from 8 of 21 patients had HLA-DR-bearing keratinocytes, often in foci
(Fig. I a). The expression of HLA-DQ antigens was also examined using mAb
161 .1, kindly provided by Dr. Laurence Jung. This mAb stained a subpopulation
of presumptive Langerhans cells and cells in the dermal infiltrate, but failed to
stain any HLA-DR' keratinocytes.
To characterize these HLA-DR' cells, double-labelling immunofluorescence
was performed with Josh 524.4 .1 and OKT6 on skin sections from eight patients.
The vast majority of epidermal cells were reactive with josh 524.4.1 (Fig. 1 b),
but not with OKT6 (Fig. 1 c). The small proportion of cells that stained with
bothJosh 524.4 .1 and OKT6 were presumably Langerhans cells (30) . The results
were confirmed with double-labelling immunofluorescence experiments using
tetramethyl-rhodamine isothiocyanate-conjugated Fab' 2 fragments of an anti-
HLA-DR antiserum and FITC-labelled OKT6. No HLA-DR' keratinocytes were
found in the normal appearing skin of six of six patients, although HLA-DR's,
OKT6+ Langerhans cells were observed in the epidermis. Studies of lesional skin
from the remaining 13 patients show that their keratinocytes were HLA-DR-.
Epidermal HLA-DR staining was not due to lymphocytes or monocytes infiltrat-
ing the epidermis, because no epidermal reactivity was observed with mAb
OKT3, 131, and 63D3, which stain peripheral T cells, B cells and monocytes,
respectively. These mAbs stained appropriate regions of sectioned lymph nodes
by the immunoperoxidase method we used.
Dermal Infiltrate of Lesional Psoriatic Skin Contains Activated T Cells, Macro-
phages, and Langerhans Cells. We also studied the dermal infiltrate of lesional
psoriatic skin. In patients with (Fig. 2a) or without (Fig. 2g) HLA-DR' kerati-101 6 HLA-DR' KERATINOCYTES AND LANGERHANS CELLS IN PSORIASIS
FIGURE 1 .
￿
Reactivity of lesional psoriatic skin with mAbs josh 524.4.1 and OKT6 . (a)
Immunoperoxidase staining of lesional skin (before treatment) from psoriasis patient MC with
mAbJosh 524 .4 .1 reveals multiple foci ofepidermal staining x 326 . (b and c) Double-labelling
immunofluorescence staining of a psoriatic plaque from patient RN . x 1,300 . The same field
is viewed after staining with mAbJosh 524.4.1 followed by tetramethyl rhodamine isothiocy-
anate-labelled Fab'2 fragments of a goat anti-mouse IgG antibody (b), and FITC-labelled
OKT6 (c) . The vast majority ofepidermal cells were reactive with mAbjosh 524.4.1, but not
mAb OKT6 .
nocytes, many OKT3+ lymphocytes were observed in pretreatment psoriatic
plaques (Fig . 2, b and h) . Essentially all of the cells in the dermal infiltrates from
both patients were stained by josh 524 .4.1, (Fig . 2, a andg) . To further confirmFIGURE 2 .
￿
Characterization of the dermal infiltrate in psoriatic plaques by immunoperoxi-
dase staining with mAbs. X 250 . Psoriatic plaque (before treatment) from patient MC stained
with (a) mAbjosh 524.4 .1 ; (b) mAb OKT3 ; (c) mAb AT-1 . Psoriatic plaque from patientMC
after 3 wk of therapy with topical tar and UV-B irradiation, and stained with (d) mAbjosh
524.4 .1 ; (e) mAb OKT3 ; (f ) mAb AT-1 . Psoriatic plaque (before treatment) from patientJE
stained with (g) mAbjosh 524.4 .1 ; (h) mAb OKT3 ; (i) mAb AT-1 . Black arrows in c and i
point to positively-stained cells .
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the presence of activated T cells, the sections were stained with mAb AT-1,
which is specific for the IL-2 receptor (25). Seven of eight patients with HLA-
DR+ keratinocytes showed significant AT-1 staining of the dermal infiltrate in
pretreatment plaques (Fig. 2c). Only a minority of cells was stained with AT-1 .
In contrast, only three of nine plaques that lacked HLA-DR+ keratinocytes were
associated with significant AT-1 staining of the dermal infiltrate (Fig. 2i). In
these three patients, the pattern of AT-1 reactivity was indistinguishable from
that seen in the dermis of patients with HLA-DR' keratinocytes. In general, the
number of AT-1-reactive cells was greatest in plaques with dense dermal infil-
trates.
Further characterization of the dermal infiltrate from active psoriatic plaques
suggested that Langerhans cells were present in addition to activated T lympho-
cytes. Psoriatic plaques from 16 of 18 patients had foci of OKT6+ cells within
the dermal infiltrate. A cluster of OKT6+ cells is evident in Fig. 3a, and is
surrounded by cells that stained with mAb OKT3 or 63D3 in serial sections (Fig.
2b). In contrast, OKT6+ cells were either absent, or present in only very low
numbers in the dermal infiltrate ofnormal-appearing skin from psoriasis patients.
Lesional skin from two patients with lichen planus, another condition character-
ized by the presence of HLA-DR' keratinocytes and activated dermal T cells,
had many OKT6+ cells in the dermal infiltrate (Fig. 3b). In addition, dermal
infiltrates from patients with contact dermatitis, spongiotic dermatitis, and ery-
thema multiforme contained foci of OKT6' cells in a pattern indistinguishable
from that seen in psoriatic plaques. Four patients with basal cell carcinoma and
one patient with squamous cell carcinoma of the lip were studied, and all had
significant numbers of OKT6+ cells scattered among the tumor islands (Fig. 3c).
Quantitation of HLA-DR Molecule Expression Using Epidermal Suction Blis-
ters. Single-cell suspensions were prepared by trypsinization of epidermal suc-
tion blisters, and were used to further characterize HLA-DR' keratinocytes. As
published previously (22), these suspensions contained <1% nonkeratinocytes.
No significant lymphocyte or monocyte contamination was present, since no
reactivity was observed with mAbs OKT3, B1, and 63D3. Cells from six of eight
active psoriasis patients with keratinocyte HLA-DR reactivity were studied (Table
I). Keratinocytes isolated from active psoriatic plaques showed a range of 7-84%
ofcells reactive with mAbJosh 524.4 .1 . <5% of the same cell population reacted
with mAb OKT6, a Langerhans cell-reactive mAb. In general, the proportion
of HLA-DR' epidermal cells in single-cell suspensions correlated with qualitative
estimatesobtained from studiesofskin biopsies. Keratinocyte suspensionsisolated
from 6 of 13 psoriatic plaques lacking HLA-DR reactivity were studied. All
contained <5% HLA-DR' cells, as did epidermal populations isolated from
normal-appearing skin from psoriasis patients and skin from three normal indi-
viduals.
Epidermal suction blisters, obtained from two separate lesional sites and one
normal-appearing area from patient MSe during relapse were studied by flow
cytometry, and the results agree with those obtained by immunofluorescence
microscopy. 36 .5% (Fig. 4c) and 21 .9% (Fig. 4d) of cells from psoriatic plaques
1 and 2, respectively, reacted with mAbJosh 524.4.1 . Only 6.3% of cells isolated
from normal-appearing skin stained positively (Fig. 4b). The negative controlGOTTLIEB ET AL.
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FIGURE 3 .
￿
Presence of Langerhans cells in the dermal infiltrates of patients with psoriasis,
lichen planus, and squamous cell carcinoma . X 270 . Immunoperoxidase staining with mAb
OKT6 of lesional skin from a patient with (a) psoriasis ; (b) lichen planus; (c) squamous cell
carcinoma of the lip. Black arrow points to positively-stained cells .
(Fig . 4a) exhibited a background staining of 3% . Staining was not due to
reactivity with contaminating activated T lymphocytes because no staining was
seen with mAb OKT3 . In all cases, there was a distinct population of cells that
was reactive with josh 524 .4.1, and one that did not stain, so that the difference
in reactivity seen between psoriatic and normal-appearing skin could not be1020 HLA-DR* KERATINOCYTES AND LANGERHANS CELLS IN PSORIASIS
TABLE I
Quantitation ofHLA-DR-bearing Keratinocytes in Single-cell
Suspensions of Cells Obtainedfrom EpidermalSuctionBlisters
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FIGURE 4.
￿
Reactivity of keratinocyte suspensions obtained from active psoriaticplaques and
uninvolved skin from patient MSe with mAbjosh 524.4.1 . Cells were stained using indirect
immunofluorescence with mAbjosh 524.4.1 followed by a 1:20 dilution of FITC-conjugated
Fab'2 fragments of a goat anti-mouse IgG antibody, and then analyzed by flow cytometry.
The ordinate depicts forward-angle light scatter (FALS) on a linear scale, and the abscissa
showslogmeasurements ofgreen fluorescence intensitydisplayed on a linear scale. (a) Control
hybridoma medium reacted with cells from psoriasis plaque 2. (b) mAbjosh 524.4.1 reacted
with uninvolved skin . (c)mAbJosh 524.4.1 reacted with cells from psoriasis plaque 1. (d) mAb
josh 524.4.1 reacted with cells from psoriasis plaque 2.
Before
treatment
After
treatment
RB 84 0.5
MSe 60 18
JK 15 ND
AF 9 1
TD 8 0
SN 7 ND
MSe 3 4
JK 1 ND
AF 1 2
TD 3 2
SN 0 NDGOTTLIEB ET AL.
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accounted for solely by a difference in intensity of staining. Frequency of HLA-
DR positivity vs. cell size (analyzed by light scattering)revealed that keratinocytes
ofall sizes contained an HLA-DR' subpopulation. However, HLA-DR molecule
expression was most frequent in the small- to mid-sized cell population, which
contains most of the epidermal stem cells (28).
HLA-DR Expression in Keratinocytesfrom Psoriatic Plaques Correlates with Disease
Activity. To determine whether HLA-DR expression in keratinocytes from
psoriatic plaques was correlated with disease activity, criteria for severe psoriasis
were established. A patient was determined to have severe psoriasis if one or
more of the following clinical signs was present: (a) coverage of >50% of the
skin with psoriatic plaques, (b) erythroderma, (c) pustular lesions, (d) psoriatic
arthritis, (e) signs of systemic illness such as fever, chills, and fluid and protein
loss. In all cases, infectious etiologies that could have given rise to the same
clinical signs were ruled out. Ofthe eight patients with HLA-DR' keratinocytes
in active plaques, six had severe disease. In particular, four ofthe eight patients
had psoriatic arthritis. In contrast, of the 12 patients lacking HLA-DR'' kerati-
nocytes, none had associated arthritis. Details of this aspect of the study will be
reported elsewhere. Five of the HLA-DR- patients had severe diseases, all of
whom were characterized by >50% ofskin coverage with psoriatic plaques. The
other seven had nonsevere disease.
The reactivity of single-cell suspensions of epidermal cells obtained from
psoriatic plaques after treatment was studied next (Table I). In all cases, the
number of HLA-DR' keratinocytes was dramatically decreased with ongoing
successful medical therapy. The effect ofdrug treatment on HLA-DR molecule
expression was further studied using immunoperoxidase experiments with mAb
josh 524.4.1, and double-labelling immunofluorescence studies with rhodamine-
conjugated Fab'2 fragments of an anti-HLA-DR antibody and fluorescein-la-
belled OKT6 on skin biopsies. Psoriatic skin (Fig. 5b) before treatment showed
intense membrane reactivity of most keratinocytes with 524.4.1 (Fig. 5a). In
contrast, psoriatic skin afterthe induction ofremission (Fig. 5 d)showed reactivity
ofonly a very small proportion ofepidermal cells (Fig. 5 c). Skin biopsies obtained
from the remaining sevenpatients with HLA-DR' keratinocytes inplaquesbefore
treatment showed similar results, although the degree of HLA-DR-reactivity
reduction varied.
Immunoperoxidase studies (Fig. 2, d-f) of the dermal infiltrate of psoriatic
plaques during successful medical therapy revealed that the infiltrate was less
dense than in active plaques before treatment. However, it was still composed of
T cells, most of which were HLA-DR', and Langerhans cells and macrophages.
In six out of eight cases, AT-1 reactivity decreased with successful therapy. In
the remaining two cases, no significant change was observed with ongoing
medical treatment.
Presence of HLA-DR' Keratinocytes in Other Inflammatory Cutaneous Disor-
ders. Other inflammatory skin diseases were tested for keratinocyte HLA-DR
expression. Skin sections from all three patients with lichen planus contained
HLA-DR' keratinocytes. HLA-DR' keratinocytes were also observed in biopsies
from spongiotic dermatitis, subcorneal pustular dermatitis, discoid lupus erythe-
matosus and lupus profundus, but not in biopsies from patients with advanced1022 HLA-DR+ KERATINOCYTES AND LANGERHANS CELLS IN PSORIASIS
FIGURE 5 .
￿
Immunofluorescence reactivity of lesional psoriatic skin from patient RB with
mAb josh 524.4 .1 before and after successful medical therapy . (a) Skin before treatment
shows intense membrane reactivity of most keratinocytes with mAbjosh 524 .4.1 . X 923. (b)
Routine formalin-fixed, paraffin-embedded, H and E-stained sections of the same skin as in
a .X 231 . (c) Lesional skin from thesame patient as in a after systemic and topical corticosteroids
and methotrexate therapy shows reactivity of only a very small proportion of epidermal cells
with mAb josh 524.4 .1 . X 923 . (d) Routine formalin-fixed, paraffin-embedded, H and E-
stained sections of same skin as in c shows remission after medical therapy . X 231 .
scleroderma(one linear, four CREST [calcinosis, Raynaud'sphenomenon, esoph-
ageal hypomotility, sclerodactyly, and telangiectasia] variants, and one progres-
sive systemic sclerosis), erythema multiforme, dermatomyositis, nummular
eczema, and cutaneous vasculitis .
Discussion
HLA-DR-bearing keratinocytes were present in plaques from one-third of
patients with active psoriasis. Immunofluorescence with two fluorochromes andGOTTLIEB ET AL.
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antibodies to HLA-DR and OKT6 antigens showed that HLA-DR molecules
were present on keratinocytes in addition to Langerhans cells. This was also
confirmed by staining keratinocytes obtained by suction blister induction. Thus,
psoriasis should be added to an increasing list of dermatoses in which HLA-DR'
keratinocytes are present (16-19). In this context, the failure of other investi-
gators to find HLA-DR' keratinocytes in psoriatic plaques needs further expla-
nation. In our patient population, a substantial number had psoriatic arthritis.
These patients belong to the patient group with HLA-DR' keratinocytes. None
of the patients lacking HLA-DR' keratinocytes had arthritis (31). In the general
psoriatic population, psoriatic arthritis is quite rare (32). Our skewed population
is due to an unusual referral pattern, in that patients with more severe skin
lesions, which are resistant to conventional therapy, are likely to be referred to
our clinic. Thus, patient selection and the limited number ofpatients studied are
the likely explanations for the inability ofother investigators to detect HLA-DR'
keratinocytes in psoriasis.
HLA-DR and HLA-DQ antigensare not detectable on keratinocytes in normal
skin. Under various pathologic conditions, HLA-DR has been detected on
keratinocytes in involved skin (16-19). Studies ofhuman delayed-type hypersen-
sitivity reactions in vivo have shown keratinocyte HLA-DR expression at only
restricted times during the course of the response (33). In the case of HLA-DQ,
its expression was not detected in this investigation on keratinocytes, despite its
presence on a subset of Langerhans cells and cells in the dermal infiltrate of
psoriatic plaques. However, in a recent publication (34), keratinocyte HLA-DQ
expression has been reported to be a late manifestation of borrelia spirochete
infection. Although the psoriasis patients in this series were studied at varying
times from the onset ofappearance ofactive plaques, thecitedstudies underscore
the need for more detailed and serial studies.
Keratinocyte HLA-DR expression correlated somewhat with disease severity,
and was reversible with successful medical therapy. Ofinterest is the observation
that, during successful medical therapy, the dermal infiltrate showed disappear-
ance of T cells with activated T cell markers. This correlation suggests that T
cells are important in the generation of psoriatic plaques. IFN-y has been shown
to induce HLA-DR expression by normal keratinocytes (35), as well as by other
epithelial cells (36-38). Recently (39), intradermal injection of recombinant IFN-
y into cutaneous lesions of patients with lepromatous leprosy has been shown to
induce HLA-DR expression by keratinocytes. Attempts to identify IFN-.y-pro-
ducing T cells and IFN-y on HLA-DR' keratinocytes in tissue sections by an
immunohistochemical technique with an mAb against IFN-y were unsuccessful.
This might be due to technical problems, such as the destruction of relevant
antigenic determinants by fixation, or inadequate section penetration. To cir-
cumvent these difficulties, in a limited number ofpatients, immunofluorescence
staining of viable keratinocyte suspensions with the anti-IFN-y was performed.
The presence of IFN-y on the surface membrane of keratinocyte populations
containing HLA-DR' cells but not those lacking HLA-DR' keratinocytes was
confirmed. Although these results are preliminary, they support the thesis that
IFN-y may be a key lymphokine in the generation of HLA-DR' keratinocytes in
psoriatic plaques. However, the possibility that other soluble mediators produced1024 HLA-DR+ KERATINOCYTES AND LANGERHANS CELLS IN PSORIASIS
by the infiltrating T cells and macrophagesmay also be responsible needs further
consideration. Studies of blister fluid composition and its ability to induce
keratinocyte HLA-DR expression, as well as those of the cellular components of
the dermal infiltrate, using mAbs against newer markers and various lympho-
kines, would be informative.
Studies ofsingle-cell suspensions of keratinocytes confirmedobservations made
using skin biopsies and quantitated the proportion of cells bearing HLA-DR
molecules. Flow cytometry experiments suggested that keratinocytes from pso-
riatic plaques, at all stages of differentiation (as judged from their sizes) were
HLA-DR'. However, the stem cell-enriched subpopulation contained the high-
est proportion of HLA-DR' cells. Thus, psoriatic epidermis contained a subpop-
ulation of HLA-DR' keratinocytes that was absent from uninvolved skin . It was
possible, however, that there was a small percentage of keratinocytes in normal-
appearing skin that expressed HLA-DR molecules, and which was expanded in
psoriatic plaques. Additional studies with basal cell layer-specific (22) and supra-
basal cell-reactive (40) mAbs will be of use in further delineating the relationship
between HLA-DR antigen expression and keratinocyte differentiation.
Our observations provide a new approach toward understanding the patho-
genesis of psoriasis, and reemphasize the role that immunologic mechanisms play
in this disease. HLA-DR' keratinocytes and Langerhans cells in active psoriatic
plaques could activate dermal T cells directly in an autologous mixed leuco-
cyte/epithelial cell reaction, or present an as-yet-unknown antigen to T lympho-
cytes. It is well known that, in a subset of patients, psoriasis flares have been
associated with antecedent streptococcal infection. T cell activation would then
lead to the release of mediators of inflammation, and possibly of epidermal
growth factors. This hypothesis would also provide an explanation for the
chronicity of psoriasis. Independent of the inciting factors, HLA-DR' keratino-
cytes could further activate dermal T cells in the absence of the etiologic agent.
Similarly, HLA-DR' adherent synovial cells can be found in thejoints of patients
with rheumatoid arthritis (41, 42), and are thought to be of importance in the
development of synovial inflammation. It is likely that HLA-DR' synovial cells
will also be found in the arthritis associated with psoriasis, and that they may
play a similar role in the pathogenesis of joint injury as do HLA-DR' keratino-
cytes in psoriatic skin.
The role of Langerhans cells needs further consideration. Langerhans cells, as
defined by reactivity with mAb OKT6, were seen in the dermal infiltrates of
patients with psoriasis, lichen planus, contact dermatitis, spongiotic dermatitis,
erythema multiforme, and basal and squamous cell carcinoma. The role of the
Langerhans cells in epidermal antigen presentation has been clearly established
(43). Ultraviolet light irradiation of the skin abrogates Langerhans cell function
(44), and in experimental animals, leads to suppression of contacthypersensitivity
and the dissemination of ultraviolet irradiation-induced basal cell carcinomas
(45). In man, sun exposure increases the incidence of keratinocyte malignancies.
Psoriasis and lichen planus are papulosquamous skin diseases of unknown etiol-
ogy, which share certain immunopathologic features, in that many HLA-DR'
epidermal keratinocytes and activated dermal T cells are evident in lesional skin
(16-18). Contact dermatitis and erythema multiforme are the result of cell-GOTTLIEB ET AL.
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mediated reactions in the skin (46, 47). It is possible that antigen, in association
with Langerhans cells, migrates to the dermis from the epidermis. Langerhans
cells can then enter the circulation and activate T cells at distal sites, e.g.,
draining lymph nodes. Once activated, T cells can migrate back to the dermis,
by mechanisms that are still unknown. Activated T lymphocytes could then
secrete IFN-T and other lymphokines that would induce HLA-DR molecule
expression by keratinocytes, in addition to promoting inflammation and epider-
mal growth. HLA-DR' keratinocytes could activate additional T lymphocytes,
accounting for the chronicity of some of these disorders. In support of this
hypothesis is the observation (G. Kaplan, R. Steinman, and Z. Cohn, personal
communication) that OKT6+ Langerhans cells are present in the dermis of
cutaneous lesions of experimentally induced delayed-type hypersensitivity reac-
tions in man. These observations may be relevant to a wide range ofdermatologic
diseases in which cell-mediated immunity plays a role.
Summary
Immunoperoxidase staining of skin sections and immunofluorescence analysis
of keratinocyte suspensions obtained from suction blisters of psoriatic plaques
were performed using an mAb, josh 524.4.1, and Fab'2 fragments of a rabbit
antiserum, both of which are directed against nonpolymorphic determinants of
HLA-DR molecules. HLA-DR' keratinocytes were present in plaques, but not
normal-appearing skin, from a significant portion of patients with active psoriasis.
Double-labelling immunofluorescence experiments with either the monoclonal
or polyclonal anti-HLA-DR antibody, in conjunction with the mAb OKT6, which
identifies DR' Langerhans cells, demonstrated that HLA-DR molecules were
present on OKT6- keratinocytes. The dermal infiltrate of psoriatic plaques
contained T cells expressing the activation antigens, IL-2 receptor (Tac) and
HLA-DR, as well as macrophages and OKT6+ cells. There was little difference
in the characteristics of the dermal infiltrate between the lesions with or without
HLA-DR' keratinocytes. OKT6' presumptive Langerhans cells were also found
in the dermal infiltrates of patients with lichen planus, contact dermatitis,
spongiotic dermatitis, erythema multiforme, basal and squamous cell carcinoma.
Studies of keratinocyte suspensions showed that 7-84% of keratinocytes were
HLA-DR'. Flow cytometry experiments showed that keratinocytes at all stages
of differentiation were HLA-DR'. However, the stem cell-enriched population
contained the highest proportion of HLA-DR' cells. HLA-DR expression by
keratinocytes correlated with disease activity. The expression was reversible with
successful medical therapy.
HLA-DR' keratinocytes may activate T cells directly or may present an as yet
unknown antigen to T cells. These studies provide further support for the
hypothesis that immunological mechanisms play an important role in the patho-
genesis of psoriasis.
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